• Vaccine Name: Classical swine fever virus vaccine VAC-E2
• Target Pathogen: Classical swine fever virus
• Target Disease: Classical swine fever, hog cholera
• Vaccine Ontology ID: VO_0011508
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Classical swine fever virus E2
• E2 gene engineering:
  • Type: Recombinant vector construction
  • Description: A 1.5-kbp DNA fragment (representing nucleotides 2433 to 3971 of CSFV Alfort Tu¨bingen) isolated from clone pHCK11 by NheI-HpaI digestion was ligated into plasmid pBR02-16/4. The resulting construct contained the nucleotide sequences for CSFV E2 and PRV-SP. Isolation of the PRV-SP E2 sequence and introduction into vector pGS62 gave rise to pGS62-E2 (König et al., 1995).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intradermal injection (i.d.)

Pig Response

• Vaccination Protocol: Pigs were vaccinated with a single dose of VVR (VAC-E0 or VAC-E2) or control strain VAC-WR by three different routes simultaneously (intradermally, intraperitoneally, and intravenously). A total of 5 x 10^7 PFU of VVR was given by each route. Clinical reactions after vaccination were monitored by daily examination (König et al., 1995).
• Challenge Protocol: The pigs were challenged intranasally 5 weeks after immunization with 2 x 10^7 50% tissue culture infective doses of CSFV Alfort Tu¨bingen. Clinical symptoms were monitored daily. Blood samples were taken at days 5 and 12 postinfection (p.i.) and at the slaughter of the animals (days 12 to 27 p.i.) (König et al., 1995).
• Efficacy: Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).